Compare Mutual Funds
Select a Mutual Fund
Risk | Very High | - |
Rating | - | - |
Min SIP Amount | ₹1000 | - |
Expense Ratio | 2.37 | - |
NAV | ₹9.73 | - |
Fund Started | 19 Nov 2024 | - |
Fund Size | ₹99.70 Cr | - |
Exit Load | Exit load of 0.50%, if redeemed within 90 days. | - |
Risk
Very High
-
Rating
-
-
Min SIP Amount
₹1000
-
Expense Ratio
2.37
-
NAV
₹9.73
-
Fund Started
19 Nov 2024
-
Fund Size
₹99.70 Cr
-
Exit Load
Exit load of 0.50%, if redeemed within 90 days.
-
1 Year | -1.21% | - |
3 Year | - | - |
5 Year | - | - |
1 Year
-1.21%
-
3 Year
-
-
5 Year
-
-
Equity | 98.07% | - |
Cash | -0.20% | - |
Equity
98.07%
-
Cash
-0.20%
-
Top 10 Holdings |
| - |
Top 10 Holdings
Sun Pharmaceutical Industries Ltd. | 11.72% |
Divi's Laboratories Ltd. | 9.97% |
Max Healthcare Institute Ltd. | 7.21% |
Aster DM Healthcare Ltd. | 6.23% |
Dr. Reddy's Laboratories Ltd. | 6.01% |
JB Chemicals & Pharmaceuticals Ltd. | 5.11% |
Mankind Pharma Ltd. | 4.65% |
Rubicon Research Ltd. | 4.29% |
Ajanta Pharma Ltd. | 3.92% |
Abbott India Ltd. | 3.61% |
-
Name | Vivek Sharma | - |
Start Date | 11 Nov 2025 | - |
Name
Vivek Sharma
-
Start Date
11 Nov 2025
-
Description | The scheme seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. | - |
Launch Date | 19 Nov 2024 | - |
Description
The scheme seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
-
Launch Date
19 Nov 2024
-